Published in Korean J Hepatol on December 01, 2010
The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data. Clin Mol Hepatol (2013) 0.97
Tissue mechanics and fibrosis. Biochim Biophys Acta (2013) 0.97
Pathophysiology of portal hypertension. Clin Liver Dis (2014) 0.91
The role of chemokines in acute and chronic hepatitis C infection. Cell Mol Immunol (2013) 0.89
Characterization of uncommon portosystemic collateral circulations in patients with hepatic cirrhosis. Oncol Lett (2014) 0.87
Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage. Dig Dis Sci (2013) 0.79
Severe portal hypertension in cirrhosis: evaluation of perfusion parameters with contrast-enhanced ultrasonography. PLoS One (2015) 0.79
Intracerebroventricular losartan infusion modulates angiotensin II type 1 receptor expression in the subfornical organ and drinking behaviour in bile-duct-ligated rats. Exp Physiol (2012) 0.78
Relationship between tetrahydrobiopterin and portal hypertension in patients with chronic liver disease. J Korean Med Sci (2014) 0.78
Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats. Dig Dis Sci (2015) 0.78
Effect of portal vein ligation on tumor growth and liver regeneration in rat cirrhotic liver lobes. Exp Ther Med (2014) 0.78
Contrast-enhanced ultrasound for quantitative assessment of portal pressure in canine liver fibrosis. World J Gastroenterol (2015) 0.77
Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? Clin Mol Hepatol (2012) 0.76
AST to Platelet Ratio Index Predicts Mortality in Hospitalized Patients With Hepatitis B-Related Decompensated Cirrhosis. Medicine (Baltimore) (2016) 0.76
Neutrophil-to-Lymphocyte Ratio Predicts Early Mortality in Patients with HBV-Related Decompensated Cirrhosis. Gastroenterol Res Pract (2016) 0.75
ANG II receptor subtype 1a gene knockdown in the subfornical organ prevents increased drinking behavior in bile duct-ligated rats. Am J Physiol Regul Integr Comp Physiol (2014) 0.75
Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis. Gut Liver (2016) 0.75
Penicillar arterioles of red pulp in residual spleen after subtotal splenectomy due to splenomegaly in cirrhotic patients: a comparative study. Int J Clin Exp Pathol (2015) 0.75
Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study. Int J Mol Med (2014) 0.75
Hepatic vein transit time of second-generation ultrasound contrast agent: new tool in the assessment of portal hypertension. J Ultrasound (2016) 0.75
Mesenteric and splenic contributions to portal venous CT perfusion in hepatic diffuse disease. Int J Clin Exp Pathol (2014) 0.75
Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut Liver (2017) 0.75
Endothelial progenitor cells: characterization and role in vascular biology. Circ Res (2004) 7.91
Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development (1999) 7.12
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
The cardiac output at rest in Laennec's cirrhosis. J Clin Invest (1953) 3.94
Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest (1998) 3.71
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology (2003) 3.66
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
Circulatory changes in chronic liver disease. Am J Med (1958) 3.43
Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J (2004) 2.80
The bone marrow functionally contributes to liver fibrosis. Gastroenterology (2006) 2.52
Isolated hepatic lipocytes and Kupffer cells from normal human liver: morphological and functional characteristics in primary culture. Hepatology (1992) 2.40
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology (2009) 2.33
Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol (1985) 1.93
Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology (2007) 1.87
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology (2006) 1.79
A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med (2005) 1.74
[Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea]. Korean J Hepatol (2008) 1.70
Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology (1998) 1.68
Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. J Clin Invest (1988) 1.60
Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology (1999) 1.58
Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology (1998) 1.57
Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology (1998) 1.47
The hepatopulmonary syndrome: new name, old complexities. Thorax (1992) 1.44
Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol (1983) 1.37
Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol (2003) 1.34
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology (2004) 1.30
Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest (1999) 1.24
Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver. Hepatology (2007) 1.23
Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut (1986) 1.19
Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology (2004) 1.18
Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis (1987) 1.17
The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther (2001) 1.09
Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology (2000) 1.07
Defects in cGMP-PKG pathway contribute to impaired NO-dependent responses in hepatic stellate cells upon activation. Am J Physiol Gastrointest Liver Physiol (2005) 1.06
Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology (1990) 1.05
Cirrhotic cardiomyopathy. Orphanet J Rare Dis (2007) 1.03
NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol (1999) 1.03
Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol (2003) 1.02
High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest (1995) 1.01
[Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension]. Korean J Gastroenterol (2009) 1.00
Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol (1997) 0.98
Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology (1994) 0.97
Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology (1999) 0.93
Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol (2005) 0.93
Nitric oxide biology and the liver: report of an AASLD research workshop. Hepatology (2004) 0.91
Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats. Gut (2003) 0.91
[Cause of death after liver transplantation: an analysis of 41 cases in 382 patients]. Zentralbl Chir (1995) 0.90
Elevated expression of caveolin-1 at protein and mRNA level in human cirrhotic liver: relation with nitric oxide. J Gastroenterol (2003) 0.89
Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology (1993) 0.88
[Pathophysiology of portal hypertension, what's new?]. Korean J Gastroenterol (2010) 0.88
Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am J Physiol (1994) 0.86
Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells. Gastroenterology (2006) 0.86
Effects of pentobarbital sodium anesthesia on splanchnic hemodynamics of normal and portal-hypertensive rats. Am J Physiol (1985) 0.86
[Assessment and current treatment of portal hypertension]. Korean J Hepatol (2005) 0.85
Activation of rat hepatic stellate cells in culture is associated with increased sensitivity to endothelin 1. Hepatology (1998) 0.85
Bioactivation of nitroglycerin and vasomotor response to nitric oxide are impaired in cirrhotic rat livers. Hepatology (2002) 0.84
Increased nitric oxide synthase expression in aorta of cirrhotic rats. Life Sci (1999) 0.82
Pathogenesis of portal hypertension. Eur J Gastroenterol Hepatol (2001) 0.82
[Cirrhotic cardiomyopathy]. Korean J Hepatol (2007) 0.81
Clinical experience of transjugular intrahepatic portosystemic shunt (TIPS) and its effects on systemic hemodynamics. Hepatogastroenterology (2004) 0.78
Portopulmonary hypertension: new clinical insights and more questions on pathogenesis. Hepatology (2003) 0.78
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: multicenter pilot study. Gastrointest Endosc (2007) 2.36
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology (2014) 2.14
Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology (2006) 1.95
Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol (2011) 1.79
[Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea]. Korean J Hepatol (2008) 1.70
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60
A nationwide seroepidemiology of hepatitis C virus infection in South Korea. Liver Int (2013) 1.57
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50
The diversity of O-linked glycans expressed during Drosophila melanogaster development reflects stage- and tissue-specific requirements for cell signaling. J Biol Chem (2008) 1.47
Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol (2012) 1.47
Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology (2003) 1.42
Journals' impact and pecking order: tyranny and tyrannosaurs. Liver Int (2012) 1.39
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions. Clin Mol Hepatol (2013) 1.35
Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. PLoS Genet (2012) 1.27
The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol (2007) 1.25
Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis. Hepatology (2012) 1.23
Cirrhotic cardiomyopathy. Semin Liver Dis (2008) 1.21
Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol (2006) 1.19
Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int (2008) 1.13
Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int (2007) 1.11
Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol (2005) 1.10
The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane. Gastrointest Endosc (2005) 1.09
Job stress and cardiovascular risk factors in male workers. Prev Med (2005) 1.07
Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis. J Gastroenterol Hepatol (2003) 1.07
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06
Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol (2006) 1.06
Risk factors for cholecystitis after metal stent placement in malignant biliary obstruction. Gastrointest Endosc (2006) 1.06
Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol (2011) 1.05
Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations. Hepatol Int (2011) 1.04
Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol (2009) 1.04
Cirrhotic cardiomyopathy. Orphanet J Rare Dis (2007) 1.03
Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol (2007) 1.02
Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study. Eur J Gastroenterol Hepatol (2015) 1.02
Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol (2005) 1.02
How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int (2013) 1.01
[Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension]. Korean J Gastroenterol (2009) 1.00
Prediction of cardiac complications after liver transplantation. Transplantation (2009) 1.00
Clinical outcomes and risk factors of rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Clin Endosc (2011) 1.00
Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol (2005) 0.99
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Amiodarone hepatotoxicity. Curr Vasc Pharmacol (2008) 0.98
Gallbladder wall thickening in patients with acute hepatitis. J Clin Ultrasound (2009) 0.98
Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study. Gut Liver (2009) 0.97
The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol (2002) 0.97
Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol (2009) 0.97
Management of hepatitis C virus genotype 4. J Gastroenterol Hepatol (2004) 0.97
Clinical features of acute viral hepatitis B in Korea: a multi-center study. Korean J Hepatol (2011) 0.97
Cirrhotic cardiomyopathy. Gastroenterol Clin Biol (2002) 0.95
Upgrade of Lesions Initially Diagnosed as Low-Grade Gastric Dysplasia upon Forceps Biopsy Following Endoscopic Resection. Gut Liver (2011) 0.94
Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis. Clin Mol Hepatol (2015) 0.94
Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) (2002) 0.93
Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study. Liver Int (2012) 0.93
Emergency management of bleeding esophageal varices: drugs, bands or sleep? Can J Gastroenterol (2006) 0.92
Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes. Diabetes Res Clin Pract (2011) 0.92
Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int (2013) 0.90
Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology (2002) 0.90
Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model. J Gastroenterol (2008) 0.90
Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data. Clin Mol Hepatol (2014) 0.90
Usefulness of Forward-Viewing Endoscope for Endoscopic Retrograde Cholangiopancreatography in Patients with Billroth II Gastrectomy. Clin Endosc (2012) 0.90
Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Korean J Hepatol (2010) 0.89
Portal vein thrombosis: should anticoagulation be used? Curr Gastroenterol Rep (2013) 0.89
Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int (2013) 0.89
Risk factors for delayed postendoscopic mucosal resection hemorrhage in patients with gastric tumor. Eur J Gastroenterol Hepatol (2007) 0.89
Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study. Gut Liver (2007) 0.89
Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus. Liver Int (2007) 0.88
Cirrhotic cardiomyopathy. Ann Hepatol (2006) 0.88
[Pathophysiology of portal hypertension, what's new?]. Korean J Gastroenterol (2010) 0.88
Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data. Clin Mol Hepatol (2013) 0.87
Effects of Korean Red Ginseng (Panax ginseng), urushiol (Rhus vernicifera Stokes), and probiotics (Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) on the gut-liver axis of alcoholic liver disease. J Ginseng Res (2014) 0.87
Anti-oxidant and natural killer cell activity of Korean red ginseng (Panax ginseng) and urushiol (Rhus vernicifera Stokes) on non-alcoholic fatty liver disease of rat. Food Chem Toxicol (2013) 0.87
Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. Cancer Discov (2013) 0.87
Clevudine demonstrates potent antiviral activity in naïve chronic hepatitis B patients. Intervirology (2009) 0.86
Endoscopic sonographic evaluation of the thickened gallbladder wall in patients with acute hepatitis. J Clin Ultrasound (2003) 0.86
Clinical features and treatment outcomes of upper gastrointestinal bleeding in patients with cirrhosis. J Korean Med Sci (2008) 0.86
Portal hypertensive gastropathy: correlation with portal hypertension and prognosis in cirrhosis. Dig Dis Sci (2010) 0.86
Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int (2008) 0.85
[Effect of endoscopic sclerotherapy using N-butyl-2-cyanoacrylate in patients with gastric variceal bleeding]. Korean J Hepatol (2006) 0.85
[Deoxycholic acid-induced signal transduction in HT-29 cells: role of NF-kappa B and interleukin-8]. Korean J Gastroenterol (2004) 0.85
Cheating in scientific publishing: the scourge must stop! Liver Int (2008) 0.85
Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology (2003) 0.85
[The survey for the actual condition of drug medication and development of health care cost associated with toxic liver injury in Korean: a multicenter study for the detection and the development of nationwide reporting system of toxic liver injury]. Korean J Hepatol (2007) 0.85
Concurrence of primary biliary cirrhosis and antiphospholipid antibody syndrome. Am J Gastroenterol (2004) 0.84
Diagnostic and Prognostic Values of Noninvasive Predictors of Portal Hypertension in Patients with Alcoholic Cirrhosis. PLoS One (2015) 0.84
Effectiveness of walking exercise as a bowel preparation for colonoscopy: a randomized controlled trial. Am J Gastroenterol (2005) 0.84
B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol (2013) 0.84
Relationship between the hepatic venous pressure gradient and first variceal hemorrhage in patients with cirrhosis: a multicenter retrospective study in Korea. Clin Mol Hepatol (2012) 0.84
Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis (2013) 0.84